Impact of Dupilumab on Healthcare Resource Utilization in Severe Asthma: Real-World Evidence in Colombia

Speaker(s)

Ali A1, Zakzuk J2, Alvis Zakzuk NJ3, Garcia E4, Diaz C5, Cano D6, Bolivar F6, Carreño A7, Rodriguez Ordonez P8, Gomez N9, Londono S8, Patiño G9, Torres C1
1Fundación Neumológica Colombiana, Bogota, Colombia, 2ALZAK Foundation, Cartagena, Colombia, 3Universidad de la Costa, Barranquilla, Colombia, 4Unidad Médico-Quirúrgica de Otorrinolaringología, Bogota, Colombia, 5NEUMOMED, Medellin, Colombia, 6Instituto Neumológico del Oriente, Bucaramanga, Colombia, 7Centro de Alergología SAS, Barranquilla, Colombia, 8Sanofi, Bogota, CUN, Colombia, 9Sanofi, Bogota, Colombia

Presentation Documents

OBJECTIVES: Severe asthma (SA) is one of the most prevalent chronic respiratory diseases worldwide, characterized by persistent symptoms and frequent exacerbations, leading to substantial healthcare resource utilization (HCRU) and economic burden. This study describes the impact of dupilumab treatment on HCRU in Colombian patients with SA.

METHODS: Retrospective observational multicentric study that included adults with SA (asthma requiring high doses of inhaled corticosteroids plus a second controller), from April 2019 to May 2023, in five Colombian centers. Data were collected from medical records at baseline and different timepoints during 24 months of treatment. Annual exacerbation rate, annual emergency room (ER) visit rate, annual hospitalization rate, intensive care unit (ICU) admissions and oral corticosteroids (OCS) consumption are reported.

RESULTS: The study enrolled 98 patients with median age of 50 years, of whom 74.5% (n=73) being women. At baseline, the annual exacerbation rate was 0.61 ± 1.45, which decreased to 0.11 ± 0.54 (reduction of 82%) during the first year and 0.08 ± 0.20 (reduction of 86.9%) after two years of follow-up. Moreover, the annualized ER visit rate and hospitalization rate decreased by 81.8% and 93.1%, respectively, after 24 months of dupilumab initiation. At baseline, ICU admissions were documented for five patients (5.1%); however, following the initiation of dupilumab, only one ICU admission was reported within the first year.

Patients requiring OCS prescriptions significantly decreased from 20.4% at baseline to 2.5% before completing the first year of treatment (8-10 months) and its consumption remained lower during the 2-year follow-up period compared to baseline.

CONCLUSIONS: By significantly reducing asthma exacerbation rates, dupilumab can lower overall HCRU, including the use of OCS and the frequency of ER visits, hospitalizations, and ICU admissions. These results highlight the dupilumab's effectiveness in managing SA and its potential to reduce the disease clinical and economic burden in Colombia.

Code

CO154

Topic

Clinical Outcomes

Topic Subcategory

Clinical Outcomes Assessment, Clinician Reported Outcomes

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)